Amylyx Pharmaceuticals Inc (AMLX)
1.76
-0.02
(-1.12%)
USD |
NASDAQ |
Apr 26, 16:00
1.755
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Shareholders Equity (Quarterly): 433.43M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 433.43M |
| September 30, 2023 | 418.40M |
| June 30, 2023 | 386.36M |
| March 31, 2023 | 352.65M |
| December 31, 2022 | 340.61M |
| September 30, 2022 | 144.03M |
| Date | Value |
|---|---|
| June 30, 2022 | 192.79M |
| March 31, 2022 | 240.95M |
| December 31, 2021 | -151.17M |
| September 30, 2021 | -124.07M |
| December 31, 2020 | -66.72M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-151.17M
Minimum
Dec 2021
433.43M
Maximum
Dec 2023
197.02M
Average
240.95M
Median
Mar 2022
Shareholders Equity (Quarterly) Benchmarks
| Cassava Sciences Inc | 137.47M |
| iRhythm Technologies Inc | 210.10M |
| Bristol-Myers Squibb Co | 16.49B |
| Moderna Inc | 13.85B |
| ACADIA Pharmaceuticals Inc | 431.76M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 517.45M |
| Total Liabilities (Quarterly) | 84.02M |
| Current Ratio | 5.664 |